Latigo Biotherapeutics, Inc.: 5AM Ventures VI, L.P. discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
5AM Ventures VI, L.P. disclosed a stake exceeding 5% in Latigo Biotherapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001753037-26-000010). The filing signals the venture firm's passive position in the clinical-stage biotech, though exact share counts and percentages were not specified in the disclosure. The move matters because 13G filings often precede broader institutional interest in small-cap biotech names. Investors will watch for further 13G/13D filings and any updates on Latigo's pipeline progress.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
5AM Ventures VI, L.P., Latigo Biotherapeutics, Inc.